Marshall Wace
BIOC

Marshall Wace’s Biocept, Inc. BIOC Stock Holding History

Marshall Wace’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,094
Closed -$215K – 4009
2022
Q1 		$215K Sell
3,094
-2,114
-41% -$166K ﹤0.01% 3077
2021
Q4 		$566K Buy
5,208
+1,709
+49% +$197K ﹤0.01% 2735
2021
Q3 		$421K Buy
+3,499
New +$408K ﹤0.01% 2478

Other funds holding BIOC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Marshall Wace's BIOC Position: Q2 2022 in Review

Marshall Wace sold out of Biocept, Inc. (BIOC) in Q2 2022, closing a stake of 3,094 shares — an estimated $215K sold.

Marshall Wace first reported a position in BIOC in Q3 2021 and held it in 3 quarters. The position peaked at $566K in Q4 2021. 27 funds tracked by Wall St. Rank hold BIOC as of Q2 2022.

  • Marshall Wace reported no remaining Biocept, Inc. position as of Q2 2022 after selling out during the quarter.
  • Marshall Wace sold 3,094 Biocept, Inc. shares in Q2 2022, an estimated $215K.
  • Marshall Wace first reported a position in Biocept, Inc. in Q3 2021 and held it in 3 quarters.
  • Marshall Wace's Biocept, Inc. position peaked at $566K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.